ArticleCell death discovery2026
RNA binding motif protein RBM41 promotes colorectal tumorigenesis by impeding the maturation of NDRG1 pre-mRNA.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a prevalent and highly lethal malignancy. RNA-binding motif (RBM) proteins have been demonstrated in CRC pathogenesis. However, the biological function and regulatory mechanisms of RBM41 in CRC remain poorly understood. Here, we demonstrate that RBM41 is significantly elevated in CRC tissues and is associated with poor prognosis in patients. Overexpression of RBM41 can enhance the malignant proliferation phenotype of CRC cells; in contrast, inhibition of RBM41 significantly decreases CRC cell proliferation and induces autophagic cell death and apoptosis in HT29 and SW480 cells. Mechanistically, RBM41 interferes with the processing of N-myc downregulated gene 1 (NDRG1) pre-mRNA by directly binding to its 3' untranslated region (3' UTR), thereby decreasing the mature transcript and protein levels of tumor suppressor NDRG1. Concurrent knockdown of NDRG1 reversed the oncogenic functions of RBM41 in HT29 cells and in fast-growing xenograft tumors in vivo. Moreover, patient-derived organoid (PDO) models with high RBM41 expression exhibited increased resistance to 5-fluorouracil, oxaliplatin, and irinotecan. In summary, our findings demonstrate that RBM41 promotes CRC progression by post-transcriptionally repressing NDRG1, underscoring its potential as a promising therapeutic target for CRC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.